The original instrument and the following digest, which constitutes no part of the
legislative instrument, were prepared by Beth O'Quin.
DIGEST
SB 154 Engrossed 2022 Regular Session Talbot
Proposed law requires any health coverage plan renewed, delivered, or issued for delivery, in this
state to include coverage for using advanced molecular techniques including but not limited to
traditional whole genome sequencing, rapid whole genome sequencing, and other genetic and
genomic screening that helps a physician timely diagnosis in and guide treatment for a critically ill
infant who is one year or younger and is receiving care in the intensive care unit or in the pediatric
care unit and the infant has a complex illness of unknown etiology.
Proposed law provides that coverage may be subject to annual deductibles, coinsurance, copayment
provisions consistent with that established under the health coverage plan and that this coverage may
be subject to applicable evidence-based medical necessity criteria based on all of the following:
(1)The infant is suspected of having a rare genetic condition not diagnosable by a standard
clinical work-up.
(2)The infant has symptoms that suggest a broad differential diagnosis that requires an
evaluation by multiple genetic tests if rWGS testing is not performed.
(3)Timely identification of a molecular diagnosis is necessary in order to guide clinical decision
making and rWGS testing results would guide the treatment or management of the infant's
condition.
(4)The infant has at least one of the following conditions:
(a)Multiple congenital anomalies.
(b)Specific malformations highly suggestive of a genetic etiology.
(c)Abnormal laboratory test suggests the presence of a genetic disease or complex
metabolic phenotype like but not limited to an abnormal newborn screen,
hyperarammonemia, or lactic acidosis not due to poor perfusion.
(d)Refractory or severe hypoglycemia.
(e)Abnormal response to therapy relates to an underlying medical condition that affects
vital organs or bodily systems.
(f)Severe hypotonia. (g)Refractory seizures.
(h)A high-risk stratification on evaluation for a brief resolved unexplained event with
any of the following:
(i)A recurrent event without respiratory infection.
(ii)A recurrent event witnessed seizure-like event.
(iii)A recurrent cardiopulmonary resuscitation.
(i)Abnormal chemistry levels like but not limited to electrolytes, bicarbonate, lactic
acid, venous blood gas, and glucose that suggest inborn error of metabolism.
(j)Abnormal cardiac diagnostic test results suggests possible channelopathies,
arrhythmias, cardiomyopathies, myocarditis, or structural heart disease.
(k)Family genetic history that relates to the infant's condition.
Proposed law defines health coverage plan as any hospital, health, or medical expense insurance
policy, hospital or medical service contract, employee welfare benefit plan, contract, or other
agreement with a health maintenance organization or a preferred provider organization, health and
accident insurance policy, or any other insurance contract of this type in the state, including group
insurance plans, self-insurance plans, and the office of group benefits programs. Excludes a plan
providing coverage for excepted benefits in present law, limited benefit health insurance plans, and
short-term policies that have a term of less than 12 months.
Proposed law applies to health coverage plans renewed, delivered, or issued for delivery in their state
on or after January 1, 2023.
Effective January 1, 2023.
(Adds R.S. 22:1028.4)
Summary of Amendments Adopted by Senate
Committee Amendments Proposed by Senate Committee on Insurance to the original bill
1. Makes technical changes.
2. Removes rapid whole genome sequencing testing, and adds advanced molecular
techniques including but not limited to traditional whole genome sequencing, rapid
whole genome sequencing, and other genetic and genomic screening.
3. Adds that all plans in this state are required to cover rapid genome sequencing testing if a provider orders the test.
4. Removes the provision that lists what is not covered by rapid whole genome
sequencing.
5. Removes the definitions for biomarker, biomarker testing, and rapid whole genome
sequencing.